Someone holds a GLP-1 pen needle in their hands.

Leading GLP-1 persistence, adherence and clinical outcomes research helps inform health plans and members

Maryam Tabatabai, PharmD, associate vice president of clinical information, offers predictions about forthcoming drug approvals, the latest on a new voucher pilot, updated biosimilar guidance and more

Jessica Johnson, clinical consultant at Prime Therapeutics, shares more about common GLP-1 fraud schemes